DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Trial Parameters
Brief Summary
This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 18 years or older 2. Diagnosis of ILD by traditional or HRCT determined by the site/institution that conducted the HRCT 3. Patients with connective tissue disease must have a baseline forced vital capacity of \<70% 4. RHC confirmed PH (mean pulmonary artery pressure \>20 mmHg, pulmonary arterial wedge pressure ≤15 mmHg, pulmonary vascular resistance \>2 WU). 5. For patients to be eligible for Cohort 1, they must not be receiving inhaled treprostinil at Baseline. 6. For patients to be eligible for Cohort 2, they must have initiated Tyvaso/Tyvaso DPI at 1 of the following time points: 1. Baseline 2. ≤60 days prior to Baseline 7. For patients to be eligible for Cohort 3, they must be receiving Tyvaso/Tyvaso DPI at Baseline and for \>60 days prior to Baseline 8. Co-enrollment in other observational or interventional studies is permitted 9. Patient is willing and able to provide informed consent and complete surveys/questionnaires in English or Spanish Exc